ADAG

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Adagene Inc

NASDAQ | ADAG

1.81

USD

$0.00

(

0.00%

)

At Close (As of Nov 19, 2025)

$84.84M

Market Cap

-

P/E Ratio

-0.64

EPS

$3.16

52 Week High

$1.30

52 Week Low

HEALTHCARE

Sector

ADAG Chart

Recent Chart
Price Action

ADAG Technicals

Tags:

ADAG Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$823K
Total Revenue $103K
Cost Of Revenue $926K
Costof Goods And Services Sold $926K
Operating Income -$36M
Selling General And Administrative $7.3M
Research And Development $29M
Operating Expenses $36M
Investment Income Net -
Net Interest Income $2.9M
Interest Income $3.8M
Interest Expense $852K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $926K
Income Before Tax -$33M
Income Tax Expense -$18K
Interest And Debt Expense -
Net Income From Continuing Operations -$33M
Comprehensive Income Net Of Tax -
Ebit -$33M
Ebitda -$32M
Net Income -$33M

Revenue & Profitability

Earnings Performance

ADAG Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $89M
Total Current Assets $88M
Cash And Cash Equivalents At Carrying Value $85M
Cash And Short Term Investments $85M
Inventory -
Current Net Receivables $8.3K
Total Non Current Assets $1.5M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $2.6M
Other Non Current Assets -
Total Liabilities $39M
Total Current Liabilities $38M
Current Accounts Payable $4.2M
Deferred Revenue -
Current Debt -
Short Term Debt $18M
Total Non Current Liabilities $560K
Capital Lease Obligations $284K
Long Term Debt $417K
Current Long Term Debt $18M
Long Term Debt Noncurrent -
Short Long Term Debt Total $18M
Other Current Liabilities $16M
Other Non Current Liabilities -
Total Shareholder Equity $51M
Treasury Stock -
Retained Earnings -$311M
Common Stock $5.9K
Common Stock Shares Outstanding $36M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$30M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $926K
Capital Expenditures $34K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $1.1M
Cashflow From Financing $3.8M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $0
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$33M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$823K
Total Revenue $103K
Cost Of Revenue $926K
Costof Goods And Services Sold $926K
Operating Income -$36M
Selling General And Administrative $7.3M
Research And Development $29M
Operating Expenses $36M
Investment Income Net -
Net Interest Income $2.9M
Interest Income $3.8M
Interest Expense $852K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $926K
Income Before Tax -$33M
Income Tax Expense -$18K
Interest And Debt Expense -
Net Income From Continuing Operations -$33M
Comprehensive Income Net Of Tax -
Ebit -$33M
Ebitda -$32M
Net Income -$33M

ADAG News

ADAG Profile

Adagene Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Adagene Inc. is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, focusing on the innovative development of monoclonal antibody therapies for oncology. Leveraging its proprietary technologies, Adagene is pioneering next-generation antibody drug candidates aimed at improving efficacy and reducing side effects in cancer treatment. With a robust pipeline of drug candidates, the company is well-positioned to make significant advancements in the biopharmaceutical landscape, targeting unmet medical needs in cancer care.

LPTX
+368.57%
$2.05
AZI
+26.74%
$0.09
FRGT
+75.73%
$1.16
PLUG
-10.98%
$1.90
CHR
+20.12%
$0.05
VHAI
-33.33%
$0.00
AXDX
-61.36%
$0.03
ZYXI
+53.23%
$0.64
AMZN
-4.43%
$222.55
DNN
-0.41%
$2.38
BURU
+14.12%
$0.23
ADAP
-15.14%
$0.05
NVDA
+2.97%
$186.75
BYND
-3.84%
$1.01
WTO
-14.13%
$0.02
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
ONDS
-1.47%
$7.72
NOK
-7.53%
$6.13
SRM
+53.27%
$10.30
IVP
-50.26%
$0.13
CRWV
-0.57%
$74.90
TWOH
+12.00%
$0.00
BTE
+3.97%
$3.14
WLGS
-5.57%
$0.04
MRK
+3.84%
$96.43
MTSR
-0.35%
$70.50
CLSK
+1.88%
$10.81
CSCO
-0.52%
$77.37
STEC
+22.42%
$0.92
BMNU
+7.65%
$8.44
SEMR
+74.77%
$11.81
GOOGL
+6.43%
$302.58
AFMD
-34.94%
$0.18
SGBX
+30.20%
$4.44
TSLA
+1.80%
$408.50
CSX
-0.05%
$33.99
ASST
-4.01%
$1.07
AGNC
+0.09%
$10.11
GOOG
+4.34%
$297.33
KZIA
+41.84%
$8.17
VSA
+2.58%
$0.17
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
TLRY
-4.84%
$0.98
NUVB
+38.85%
$6.66
CAN
-4.36%
$0.98
ALIT
-5.14%
$2.03
PCG
-1.54%
$15.90
BITF
-1.81%
$2.70
SOFI
+0.89%
$26.47
ETHD
+10.54%
$5.78
WULF
+4.02%
$12.48
XPEV
+0.84%
$22.62
SAND
-6.04%
$12.12
CRCL
-8.61%
$70.00
BMNR
-4.21%
$30.92
IREN
+1.54%
$49.60
QUBT
-3.32%
$11.93
SHOT
-74.37%
$0.39
DVLT
-8.28%
$1.60
OWL
-3.09%
$13.48
ASBP
-7.09%
$0.09
ZAPP
-46.30%
$0.15
MU
-0.37%
$227.63
LRCX
-2.86%
$143.24
PLTR
+0.84%
$168.74
HL
+0.57%
$14.06
INTC
+3.63%
$35.57
AAPL
+0.85%
$269.71
ACHR
-1.51%
$7.49
EOSE
-0.29%
$13.44
CCCS
+2.42%
$7.19
GPUS
-1.08%
$0.23
MARA
-3.75%
$11.43
STLA
-2.40%
$9.74
CIFR
+4.49%
$15.23
PEP
+0.63%
$148.77
SOUN
+1.38%
$11.68
RGTI
+3.42%
$26.59
MP
+10.86%
$64.87
MDLZ
+0.37%
$55.78
SNAP
-1.03%
$8.16
QBTS
+6.29%
$24.37
NIO
-1.83%
$5.87
OLMA
+14.74%
$23.11
APLD
+3.08%
$23.54
TE
-3.77%
$3.06
SMR
-1.44%
$21.22
NAKA
+1.21%
$0.56
KDLY
+1.21%
$0.56
CANF
-18.67%
$0.30
BTBT
-8.15%
$2.18
KLAR
-9.31%
$31.63
QS
-2.92%
$12.59
FL
-0.37%
$24.01
IONZ
+0.63%
$4.80
TGT
-0.63%
$87.96
ETHE
+4.05%
$25.64
LPTX
+368.57%
$2.05
AZI
+26.74%
$0.09
FRGT
+75.73%
$1.16
PLUG
-10.98%
$1.90
CHR
+20.12%
$0.05
VHAI
-33.33%
$0.00
AXDX
-61.36%
$0.03
ZYXI
+53.23%
$0.64
AMZN
-4.43%
$222.55
DNN
-0.41%
$2.38
BURU
+14.12%
$0.23
ADAP
-15.14%
$0.05
NVDA
+2.97%
$186.75
BYND
-3.84%
$1.01
WTO
-14.13%
$0.02
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
ONDS
-1.47%
$7.72
NOK
-7.53%
$6.13
SRM
+53.27%
$10.30
IVP
-50.26%
$0.13
CRWV
-0.57%
$74.90
TWOH
+12.00%
$0.00
BTE
+3.97%
$3.14
WLGS
-5.57%
$0.04
MRK
+3.84%
$96.43
MTSR
-0.35%
$70.50
CLSK
+1.88%
$10.81
CSCO
-0.52%
$77.37
STEC
+22.42%
$0.92
BMNU
+7.65%
$8.44
SEMR
+74.77%
$11.81
GOOGL
+6.43%
$302.58
AFMD
-34.94%
$0.18
SGBX
+30.20%
$4.44
TSLA
+1.80%
$408.50
CSX
-0.05%
$33.99
ASST
-4.01%
$1.07
AGNC
+0.09%
$10.11
GOOG
+4.34%
$297.33
KZIA
+41.84%
$8.17
VSA
+2.58%
$0.17
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
TLRY
-4.84%
$0.98
NUVB
+38.85%
$6.66
CAN
-4.36%
$0.98
ALIT
-5.14%
$2.03
PCG
-1.54%
$15.90
BITF
-1.81%
$2.70
SOFI
+0.89%
$26.47
ETHD
+10.54%
$5.78
WULF
+4.02%
$12.48
XPEV
+0.84%
$22.62
SAND
-6.04%
$12.12
CRCL
-8.61%
$70.00
BMNR
-4.21%
$30.92
IREN
+1.54%
$49.60
QUBT
-3.32%
$11.93
SHOT
-74.37%
$0.39
DVLT
-8.28%
$1.60
OWL
-3.09%
$13.48
ASBP
-7.09%
$0.09
ZAPP
-46.30%
$0.15
MU
-0.37%
$227.63
LRCX
-2.86%
$143.24
PLTR
+0.84%
$168.74
HL
+0.57%
$14.06
INTC
+3.63%
$35.57
AAPL
+0.85%
$269.71
ACHR
-1.51%
$7.49
EOSE
-0.29%
$13.44
CCCS
+2.42%
$7.19
GPUS
-1.08%
$0.23
MARA
-3.75%
$11.43
STLA
-2.40%
$9.74
CIFR
+4.49%
$15.23
PEP
+0.63%
$148.77
SOUN
+1.38%
$11.68
RGTI
+3.42%
$26.59
MP
+10.86%
$64.87
MDLZ
+0.37%
$55.78
SNAP
-1.03%
$8.16
QBTS
+6.29%
$24.37
NIO
-1.83%
$5.87
OLMA
+14.74%
$23.11
APLD
+3.08%
$23.54
TE
-3.77%
$3.06
SMR
-1.44%
$21.22
NAKA
+1.21%
$0.56
KDLY
+1.21%
$0.56
CANF
-18.67%
$0.30
BTBT
-8.15%
$2.18
KLAR
-9.31%
$31.63
QS
-2.92%
$12.59
FL
-0.37%
$24.01
IONZ
+0.63%
$4.80
TGT
-0.63%
$87.96
ETHE
+4.05%
$25.64
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.